Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
about
Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with nonspecific elevations of prostate-specific antigen levelsTwenty Years of PSA: From Prostate Antigen to Tumor MarkerCurrent status of biomarkers for prostate cancerChanges in prostate gene expression in men undergoing an intensive nutrition and lifestyle interventionProteomics and peptidomics: moving toward precision medicine in urological malignanciesThe Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology AdvancementsImmunochemical Assays and Nucleic-Acid Detection Techniques for Clinical Diagnosis of Prostate CancerPSA and beyond: alternative prostate cancer biomarkersEmerging PSA-based tests to improve screeningLandmarks in prostate cancer diagnosis: the biomarkersKallikreins as biomarkers for prostate cancerMass spectrometry for translational proteomics: progress and clinical implicationsUrinary biomarkers for prostate cancerA Magnetic Bead-Based Sensor for the Quantification of Multiple Prostate Cancer Biomarkers.Tumour biomarkers: homeostasis as a novel prognostic indicatorHow Precisely Can Prostate Cancer Be Managed?Shiftwork and prostate-specific antigen in the National Health and Nutrition Examination SurveyArtificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocityExternal validation and head-to-head comparison of Japanese and Western prostate biopsy nomograms using Japanese data sets.Methods for Assessing Improvement in Specificity when a Biomarker is Combined with a Standard Screening Test.Analysis of DNA Methylation Status in Bodily Fluids for Early Detection of CancerGamma-glutamyltransferase activity in exosomes as a potential marker for prostate cancerMetabolomic characterization of human prostate cancer bone metastases reveals increased levels of cholesterol.The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study.A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressivenessAssociation of urinary phytoestrogen concentrations with serum concentrations of prostate-specific antigen in the National Health and Nutrition Examination Survey.Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literatureFactors influencing the acceptance of transrectal ultrasound-guided prostate biopsies.The Gordon Wilson Lecture. Natural history and treatment of early stage prostate cancer.Legal pitfalls in the diagnosis of prostate cancer.The clinical impact of different assays for prostate specific antigen.The role of empiric antibiotic treatment in preventing unnecessary prostate biopsies in asymptomatic patients with PSA levels between 4 and 10 ng/ml.Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy.A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detectionMicrofluidic force spectroscopy for characterization of biomolecular interactions with piconewton resolution.Porous silicon antibody microarrays for quantitative analysis: measurement of free and total PSA in clinical plasma samplesThe role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease.Initial biopsy outcome prediction in Korean patients-comparison of a noble web-based Korean prostate cancer risk calculator versus prostate-specific antigen testing.Potential utility of cancer-specific biomarkers for assessing response to hormonal treatments in metastatic prostate cancer.An inexpensive, fast and sensitive quantitative lateral flow magneto-immunoassay for total prostate specific antigen
P2860
Q24550631-29390F92-DDF4-4550-B0FE-DC68F904A804Q24564782-CB827DFA-14A3-4BAD-9937-2480E77D6309Q24600574-4C3C3EBD-44FB-4F3D-B5E8-DA30AD10832FQ24653994-993384BA-69F7-4DAC-8807-8292463403DAQ26749401-AB8C853A-2F0C-49DB-AB92-8286790312B9Q26750672-D1A56991-84CE-427E-B27C-F51CEE16F0F1Q26767044-20D195AE-66CE-4862-B038-664D93E0572BQ26770646-6D2408AB-8255-46A3-8E18-80B1327819DDQ26828563-B6CEF8E2-25E2-4ED1-A664-10E3FE0E9027Q26852523-54708D7A-D12C-4B27-B1BB-426271D59211Q26862434-BB6AE156-315F-46AC-9540-23A2F8C86186Q26995497-22B82A63-9C72-4D55-93D4-318198A7A318Q27009110-98C4FD59-57F8-4FE5-A04E-9DE24E5DF942Q27315819-242076E8-CEBE-4E17-8F0B-2E2A42F87EFCQ28069898-AC8A9336-6028-43C5-A940-38C7190DB611Q28078942-F37D2758-B7BF-4715-A9F7-8B924CA0989EQ28392746-736B44C1-19B9-4E13-A86F-EB5E993F6192Q33365802-0EB3E941-60D9-4542-8FDE-5CBFE3D656FFQ33410362-7A7F0612-8F6B-4D1B-90FC-FC8F14A0831FQ33573087-6A3273A3-FDF1-488D-81FE-5223706AD237Q33624423-B53CE1A7-66A2-4639-A319-460B6A787194Q33644807-14044FAC-B13E-479C-A19A-D1960147F086Q33769607-B299E1C7-DDE5-4A23-8562-0F84BCC67BA9Q33810503-E72FB86F-8815-440E-A70C-87B9F2550892Q33839248-FE4F82C5-5DFB-49B7-B233-1AA1CF03384CQ33862301-708EF895-CF5A-46A8-A787-61BE667E77E5Q33911725-6DD77B88-D9C0-4C42-B265-D207DF4B8E69Q33911742-DD153BF8-4A5E-4382-BACA-0E7861DBD9B9Q33958709-FDD81708-505F-4725-B731-9CA3BDB8A13EQ33994245-1ED00E1D-53FE-4063-A949-269276F683AEQ34022442-F8FEA26C-BAA7-4522-B1FC-AC7CEF7863BEQ34167201-EB01D221-1416-4E66-91D3-140B7265150DQ34225923-8A7AFF21-4975-4139-B633-F81D4DD66309Q34294196-8C34C309-DDA0-45DE-9669-792DC8BEC08AQ34335987-946B5027-6124-4EDD-A57A-1F26BC7E299BQ34361084-2FED58CC-72AB-4B36-A873-B161E3068E29Q34447102-F1F694FF-BB4D-4264-8850-35B7FA2A6D4AQ34451940-B87992C2-1D85-4844-97CA-EF4978005C9AQ34536729-FF3924EB-A128-4153-A9C8-ADE6E03014A2Q34686686-1A88E720-3275-4BE2-A145-A20CE285A5BB
P2860
Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.
description
1998 nî lūn-bûn
@nan
1998 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Use of the percentage of free ...... ve multicenter clinical trial.
@ast
Use of the percentage of free ...... ve multicenter clinical trial.
@en
Use of the percentage of free ...... ve multicenter clinical trial.
@nl
type
label
Use of the percentage of free ...... ve multicenter clinical trial.
@ast
Use of the percentage of free ...... ve multicenter clinical trial.
@en
Use of the percentage of free ...... ve multicenter clinical trial.
@nl
prefLabel
Use of the percentage of free ...... ve multicenter clinical trial.
@ast
Use of the percentage of free ...... ve multicenter clinical trial.
@en
Use of the percentage of free ...... ve multicenter clinical trial.
@nl
P2093
P356
P1476
Use of the percentage of free ...... ve multicenter clinical trial.
@en
P2093
A W Partin
E N Subong
G H Gasior
J B deKernion
J P Richie
K G Loveland
K M Slawin
M K Brawer
P C Southwick
P304
P356
10.1001/JAMA.279.19.1542
P407
P577
1998-05-01T00:00:00Z